Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying […]
Samyang Holdings Enters Partnership with LG Chem for the Development of Innovative Cancer Therapeutics
Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on […]
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Tubulis and Bristol Myers Squibb today announced that they have entered into a strategic license […]
Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate
Nutcracker Therapeutics, a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology […]
Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101
Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable […]
ZAP Surgical Announces 1,000th Patient Treated with Its Groundbreaking ZAP-X Gyroscopic Radiosurgery Platform
ZAP Surgical Systems, a leading innovator in the field of surgical robotics, today announced that […]
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
IDEAYA Biosciences, a precision medicine oncology company committed to the discovery and development of targeted […]
Maxion Therapeutics Awarded £2 Million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-To-Treat" Autoimmune Diseases
Biotechnology company Maxion Therapeutics has announced it has been awarded a prestigious GBP £2 million […]
TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
MapKure, BeiGene and SpringWorks Therapeutics, today announced that they will present updated clinical data from the […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more